title: Amyloid-Independent Amnestic Mild Cognitive Impairment and Serum Apolipoprotein A1 Levels.
abstract: OBJECTIVE
  The present study investigated the characteristics of amnestic mild cognitive impairment (aMCI) in subjects with low brain amyloid-beta (Aβ) burden. Furthermore, the relationships between amyloid-independent cognitive decline and serum lipid profiles, particularly apolipoprotein A1 (APOA1), were evaluated.
  
  
  METHODS
  Cross-sectional and longitudinal follow-up study.
  
  
  METHODS
  University hospital dementia clinic.
  
  
  METHODS
  28 aMCI and 35 cognitive normal (CN) elderly.
  
  
  METHODS
  The study measures included baseline assessments of the subjects' clinical characteristics, lipid profiles, and magnetic resonance imaging and (11)C-labelled Pittsburgh Compound B (PiB) positron emission tomography scans. Based on PiB retention at baseline, the aMCI subjects were divided into low Aβ (aMCI-) and high Aβ (aMCI+) subgroups. All aMCI subjects were followed up over a 1-year period.
  
  
  RESULTS
  The aMCI- group had a longer duration of illness than did the aMCI+ group. None of the aMCI- subjects were diagnosed with Alzheimer disease (AD) dementia during the 1-year follow-up period, whereas 26.7% of aMCI+ subjects developed AD dementia. The aMCI- group also exhibited lower serum APOA1 levels compared with both the aMCI+ and CN groups. Additionally, lower serum APOA1 levels were associated with cognitive decline and brain atrophy independent of Aβ deposition and vascular burden.
  
  
  CONCLUSIONS
  Patients with aMCI- likely exhibit different clinical and pathophysiological characteristics than patients with aMCI+. Additionally, APOA1 may be an important contributor underlying amyloid-independent neurodegeneration.
authors.affiliation: Department of Neuropsychiatry, Seoul National University Hospital & Seoul National University College of Medicine, Seoul, Korea.
authors.forename: Hyo Jung
authors.initials: HJ
authors.lastname: Choi
authors.affiliation: Division of Natural Medical Sciences, College of Health Science, Chosun University, Gwangju, Korea.
authors.forename: Eun Hyun
authors.initials: EH
authors.lastname: Seo
authors.affiliation: Department of Neuropsychiatry, Seoul National University Hospital & Seoul National University College of Medicine, Seoul, Korea.
authors.forename: Dahyun
authors.initials: D
authors.lastname: Yi
authors.affiliation: Department of Neuropsychiatry, Seoul Metropolitan BORAMAE Medical Center, Dongjak-Gu, Seoul, Korea.
authors.forename: Bo Kyung
authors.initials: BK
authors.lastname: Sohn
authors.affiliation: Department of Neuropsychiatry, Seoul National University Hospital & Seoul National University College of Medicine, Seoul, Korea.
authors.forename: Young Min
authors.initials: YM
authors.lastname: Choe
authors.affiliation: Department of Neuropsychiatry, Seoul National University Hospital & Seoul National University College of Medicine, Seoul, Korea.
authors.forename: Min Soo
authors.initials: MS
authors.lastname: Byun
authors.affiliation: Department of Biomedical Engineering, Hanyang University, Seoul, Korea.
authors.forename: Jong Min
authors.initials: JM
authors.lastname: Lee
authors.affiliation: Department of Neuropsychiatry, Seoul National University Hospital & Seoul National University College of Medicine, Seoul, Korea.
authors.forename: Jong Inn
authors.initials: JI
authors.lastname: Woo
authors.affiliation: Department of Neuropsychiatry, Seoul National University Hospital & Seoul National University College of Medicine, Seoul, Korea. Electronic address: selfpsy@snu.ac.kr.
authors.forename: Dong Young
authors.initials: DY
authors.lastname: Lee
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000175:diagnosis*; D000647:Amnesia / Q000097:blood*; D000682:Amyloid / Q000378:metabolism*; D000814:Aniline Compounds / Q000008:administration & dosage; D016632:Apolipoprotein A-I / Q000097:blood*; D001284:Atrophy; D001921:Brain / Q000473:pathology*; D001931:Brain Mapping; D060825:Cognitive Dysfunction / Q000097:blood*; D003430:Cross-Sectional Studies; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016014:Linear Models; D008137:Longitudinal Studies; D008279:Magnetic Resonance Imaging; D008297:Male; D009483:Neuropsychological Tests; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals / Q000008:administration & dosage; D013844:Thiazoles / Q000008:administration & dosage
chemical_list: C475519:2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole; C505693:APOA1 protein, human; D000682:Amyloid; D000814:Aniline Compounds; D016632:Apolipoprotein A-I; D019275:Radiopharmaceuticals; D013844:Thiazoles
keywords: Alzheimer disease; Amyloid PET; MRI; apolipoprotein; mild cognitive impairment